Contemporary management of atrial fibrillation: Update on anticoagulation and invasive management strategies

Mayo Clinic Proceedings

Volumn 84, Issue 7, 2009, Pages 643-662

  Crandall, Mark A ^a   Bradley, David J ^a   Packer, Douglas L ^a   Asirvatham, Samuel J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CORTICOSTEROID; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; ENCAINIDE; FISH OIL; FLECAINIDE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; TEDISAMIL; VERAPAMIL; WARFARIN; ANTICOAGULANT AGENT;

ADD ON THERAPY; ANTICOAGULANT THERAPY; AUTONOMIC DYSFUNCTION; BLEEDING; BRAIN HEMORRHAGE; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CARDIOVERSION; CAROTID ARTERY; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DEFIBRILLATOR; DIASTOLIC DYSFUNCTION; DIRECT CURRENT; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRINKING BEHAVIOR; DRUG DOSE TITRATION; DRUG WITHDRAWAL; ELECTRIC SHOCK; ELECTROCARDIOGRAPHY MONITORING; ESOPHAGUS FISTULA; FATIGUE; GENE MAPPING; HEART ATRIUM CONTRACTION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART ATRIUM FUNCTION; HEART FAILURE; HEART PALPITATION; HEART RATE; HEART RHYTHM; HEMATOMA; HEMODYNAMIC MONITORING; HEMOSTASIS; HEREDITY; HUMAN; HYPERTENSION; HYPERTHYROIDISM; INFECTION; INFLAMMATION; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MITRAL VALVE; MITRAL VALVE DISEASE; MORTALITY; MULTIFACTORIAL INHERITANCE; OBESITY; OXIDATIVE STRESS; PACEMAKER; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PATHOPHYSIOLOGY; PATIENT SELECTION; PNEUMOTHORAX; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREVALENCE; PROSTHETIC VALVE THROMBOSIS; PULMONARY VEIN; PULMONARY VEIN OBSTRUCTION; QRS COMPLEX; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RHEUMATIC HEART DISEASE; RISK ASSESSMENT; RISK FACTOR; SINUS RHYTHM; SLEEP APNEA SYNDROME; STROKE; SUPERIOR CAVA VEIN; TACHYCARDIA; THROMBOEMBOLISM; THROMBUS; TREATMENT OUTCOME; ELECTROCARDIOGRAPHY; REVIEW;

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; HUMANS; RISK FACTORS;

EID: 67650755000     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.7.643     Document Type: Conference Paper

References (185)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-2375.
2. Jahangir A, Lee V, Friedman PA, et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation. 2007;115(24):3050-3056. Epub 2007 Jun 4.
3. European Heart Rhythm Association; Heart Rhythm Society; Fuster V, Rydén LE, Cannom DS, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) [published correction appears in J Am Coll Cardiol. 2007;50(6):562]. J Am Coll Cardiol. 2006;48(4):854-906.
4. Al-Khatib SM, Wilkinson WE, Sanders LL, McCarthy EA, Pritchett EL. Observations on the transition from intermittent to permanent atrial fibrillation. Am Heart J. 2000;140(1):142-145.
5. Kerr CR, Humphries KH, Talajic M, et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J. 2005;149(3):489-496.
6. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL; Stroke Prevention in Atrial Fibrillation Investigators. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol. 2000;35(1):183-187.
7. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation. 1995;92(7):1954-1968.
8. Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659-666.
9. Aidietis A, Laucevicius A, Marinskis G. Hypertension and cardiac arrhythmias. Curr Pharm Des. 2007;13(25):2545-2555.
10. Hennersdorf MG, Schueller PO, Steiner S, Strauer BE. Prevalence of paroxysmal atrial fibrillation depending on the regression of left ventricular hypertrophy in arterial hypertension. Hypertens Res. 2007;30(6):535-540.
11. McCarthy PM, Kruse J. Atrial fibrillation in patients with coronary disease. J Interv Card Electrophysiol. 2007;20(30):113-117.
12. Budaj A, Flasinska K, Gore JM, et al; GRACE Investigators. Magnitude of and risk factors for in-hospital and postdischarge stroke in patients with acute coronary syndromes: findings from a Global Registry of Acute Coronary Events. Circulation. 2005;111(24):3242-3247. Epub 2005 Jun 13.
13. Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation and obesity - results of a meta-analysis. Am Heart J. 2008;155(2):310-315. Epub 2007 Dec 19.
14. Orban M, Bruce CJ, Pressman GS, et al. Dynamic changes of left ventricular performance and left atrial volume induced by the mueller maneuver in healthy young adults and implications for obstructive sleep apnea, atrial fibrillation, and heart failure. Am J Cardiol. 2008;102(11):1557-1561. Epub 2008 Sep 15.
15. Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J. 2001;142(5):838-842.
16. Gammage MD, Parle JV, Holder RL, et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med. 2007;167(9):928-934.
17. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials: Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;32(3):695-703.
18. Olsson LG, Swedberg K, Ducharme A, et al. CHARM Investigators. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006;47(10):1997-2004. Epub 2006 Apr 27.
19. Diker E, Aydogdu S, Ozdemir M, et al. Prevalence and predictors of atrial fibrillation in rheumatic valvular heart disease. Am J Cardiol. 1996;77(1):96-98.
20. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) [published correction appears in Circulation. 2007;115(15):e409]. Circulation. 2006;114(5):e84- e231.
21. Grigioni F, Avierinos JF, Ling LH, et al. Atrial fibrillation complicating the course of degenerative mitral regurgitation: determinants and long-term outcome. J Am Coll Cardiol. 2002;40(1):84-92.
22. Alexiou C, Doukas G, Oc M, et al. The effect of preoperative atrial fibrillation on survival following mitral valve repair for degenerative mitral regurgitation. Eur J Cardiothorac Surg. 200 Apr;31(4):586-591. Epub 2007 Feb 5.
23. Otto CM. Valvular aortic stenosis: disease severity and timing of intervention. J Am Coll Cardiol. 2006;47(11):2141-2151. Epub 2006 May 15.
24. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42(9):1687-1713.
25. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517-2524.
26. Hravnak M, Hoffman LA, Saul MI, Zullo TG, Whitman GR, Griffith BP. Predictors and impact of atrial fibrillation after isolated coronary artery bypass grafting. Crit Care Med. 2002;30(2):330-337.
27. Jongnarangsin K, Oral H. Postoperative atrial fibrillation. Med Clin North Am. 2008;92(1):87-99, x-x1.
28. Burgess DC, Kilborn MJ, Keech AC. Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. Eur Heart J. 2006;27(23):2846-2857. Epub 2006 Oct 2.
29. Halonen J, Halonen P, Järvinen O, et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. JAMA. 2007;297(14):1562-1567.
30. Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol. 2008;126(2):160-170. Epub 2007 Nov 26.
31. Yared JP, Bakri MH, Erzurum SC, et al. Effect of dexamethasone on atrial fibrillation after cardiac surgery: prospective, randomized, double-blind, placebo-controlled trial. J Cardiothorac Vasc Anesth. 2007;21(1):68-75. Epub 2006 Feb 14.
32. Chen PS, Tan AY. Autonomic nerve activity and atrial fibrillation. Heart Rhythm. 2007;4:S61-S64. Epub 2006 Dec 15.
33. Scherlag BJ, Nakagawa H, Jackman WM, et al. Electrical stimulation to identify neural elements on the heart: their role in atrial fibrillation. J Interv Card Electrophysiol. 2005;13(suppl 1):37-42.
34. Olson TM, Alekseev AE, Moreau C, et al. KATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2007;4(2):110-116.
35. Segerson NM, Sharma N, Smith ML, et al. The effects of rate and irregularity on sympathetic nerve activity in human subjects. Heart Rhythm. 2007;4(1):20-26. Epub 2006 Sep 16.
36. Wasmund SL, Li JM, Page RL, et al. Effect of atrial fibrillation and an irregular ventricular response on sympathetic nerve activity in human subjects. Circulation. 2003;107(15):2011-2015. Epub 2003 Apr 7.
37. Djoussé L, Levy D, Benjamin EJ, et al. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. Am J Cardiol. 2004;93(6):710-713.
38. Mukamal KJ, Psaty BM, Rautaharju PM, et al. Alcohol consumption and risk and prognosis of atrial fibrillation among older adults: the Cardiovascular Health Study. Am Heart J. 2007;153(2):260-266.
39. Frost L, Vestergaard P. Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr. 2005;81(3):578-582.
40. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol. 2007;50(21):2021-2028. Epub 2007 Nov 5.
41. Anderson JL, Allen Maycock CA, Lappé DL, et al. Frequency of elevation of C-reactive protein in atrial fibrillation. Am J Cardiol. 2004;94(10):1255-1259.
42. Asselbergs FW, van den Berg MP, Diercks GF, van Gilst WH, van Veldhuisen DJ. C-reactive protein and microalbuminuria are associated with atrial fibrillation. Int J Cardiol. 2005;98(1):73-77.
43. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108(24):3006-3010. Epub 2003 Nov 17.
44. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104(24):2886-2891.
45. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J. 2006;27(5):512-518. Epub 2005 Nov 25.
46. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation. 2000;101(22):2612-2617.
47. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol. 2003;41(12):2197-2204.
48. Kawamura M, Ito H, Onuki T, et al. Combination therapy of renin angiotensin system inhibitors and bepridil is useful for maintaining sinus rhythm in patients with atrial fibrillation. J Cardiol. 2007;50(6):343-350.
49. Fox CS, Parise H, D'Agostino RB Sr, et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA. 2004;291(23):2851-2855.
50. Brugada R. Is atrial fibrillation a genetic disease? J Cardiovasc Electrophysiol. 2005;16(5):553-556.
51. Roberts R. Mechanisms of disease: genetic mechanisms of atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2006;3(5):276-282.
52. Rho RW, Page RL. Asymptomatic atrial fibrillation. Prog Cardiovasc Dis. 2005;48(2):79-87.
53. Israel CW, Grönefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol. 2004;43(1):47-52.
54. Calò L, De Ruvo E, Sette A, et al. Tachycardia-induced cardiomyopathy: mechanisms of heart failure and clinical implications. J Cardiovasc Med (Hagerstown). 2007;8(3):138-143.
55. Rothman SA, Laughlin JC, Seltzer J, et al. The diagnosis of cardiac arrhythmias: a prospective multi-center randomized study comparing mobile cardiac outpatient telemetry versus standard loop event monitoring. J Cardiovasc Electrophysiol. 2007;18(3):241-247.
56. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-952.
57. Frost L, Engholm G, Johnsen S, Møller H, Husted S. Incident stroke after discharge from the hospital with a diagnosis of atrial fibrillation. Am J Med. 2000;108(1):36-40.
58. Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol. 2007;6(11):981-993.
59. Kasper EK, Agema WR, Hutchins GM, Deckers JW, Hare JM, Baughman KL. The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol. 1994;23(3):586-590.
60. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006;119(5):448.e1- 448.e19.
61. Jenkins LS, Brodsky M, Schron E, et al. Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149(1):112-120.
62. Raghavan AV, Decker WW, Meloy TD. Management of atrial fibrillation in the emergency department. Emerg Med Clin North Am. 2005;23(4):1127-1139.
63. Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med. 2004;351(23):2384-2391.
64. Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation. 2004;110(4):364-367. Epub 2004 Jul 12.
65. Boriani G, Diemberger I, Biffi M, et al. Electrical cardioversion for persistent atrial fibrillation or atrial flutter in clinical practice: predictors of long-term outcome. Int J Clin Pract. 2007;61(5):748-756.
66. Kim SS, Knight BP. Electrical and pharmacologic cardioversion for atrial fibrillation. Med Clin North Am. 2008;92(1):101-120.
67. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988.
68. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation: 30-year follow-up in the Framingham Study. JAMA. 1985;254(24):3449-3453.
69. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation: the Framingham Study. Stroke. 1996;27(10):1760-1764.
70. Anderson DC, Kappelle LJ, Eliasziw M, Babikian VL, Pearce LA, Barnett HJ. Occurrence of hemispheric and retinal ischemia in atrial fibrillation compared with carotid stenosis. Stroke. 2002;33(8):1963-1967.
71. Atrial Fibrillation Investigators; Atrial Fibrillation, Aspirin, Anticoagulation Study; European Atrial Fibrillation Study; Stroke Prevention in Atrial Fibrillation Study; Boston Area Anticoagulation Trial for Atrial Fibrillation Study; Canadian Atrial Fibrillation Study; Veterans Affairs Prevention in Atrial Fibrillation Study. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med. 1998;158(12):1316-1320.
72. Mitusch R, Siemens HJ, Garbe M, Wagner T, Sheikhzadeh A, Diederich KW. Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost. 1996;75(2):219-223.
73. Uno M, Tsuji H, Sawada S, Toyoda T, Nakagawa M. Fibrinopeptide A (FPA) levels in atrial fibrillation and the effects of heparin administration. Jpn Circ J. 1988;52(1):9-12.
74. Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med. 1998;128(8):639-647.
75. Atrial Fibrillation Investigators; Atrial Fibrillation, Aspirin, Anticoagulation Study; Boston Area Anticoagulation Trial for Atrial Fibrillation Study; Canadian Atrial Fibrillation Anticoagulation Study; Stroke Prevention in Atrial Fibrillation Study; Veterans Affairs Prevention in Nonrheumatic Atrial Fibrillation Study Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials [published correction appears in Arch Intern Med. 1994;154(19):2254]. Arch Intern Med. 1994;154(13):1449-1457.
76. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348(9028):633-638.
77. SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA. 1998;279(16):1273-1277.
78. Casella L, Abelmann WH, Ellis LB. Patients with mitral stenosis and systemic emboli: hemodynamic and clinical observations. Arch Intern Med. 1964;114:773-781.
79. Daley R, Mattingly TW, Holt CL, Bland EF, White PD. Systemic arterial embolism in rheumatic heart disease. Am Heart J. 1951;42(4):566-581.
80. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-2870.
81. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290(20):2685-2692.
82. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7):492-501.
83. Polanczyk CA, Goldman L, Marcantonio ER, Orav EJ, Lee TH. Supraventricular arrhythmia in patients having noncardiac surgery: clinical correlates and effect on length of stay. Ann Intern Med. 1998;129(4):279-285.
84. Ezekowitz MD, Bridgers SL, James KE, et al; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation [published correction appears in N Engl J Med. 1993;328(2):148]. N Engl J Med. 1992;327(20):1406-1412.
85. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323(22):1505-1511.
86. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation. 1991;84(2):527-539.
87. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342(8882):1255-1262.
88. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343(8899):687- 691.
89. Diener HC. Antiplatelet agents and randomized trials. Rev Neurol Dis. 2007;4(4):177-183.
90. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1(8631):175-179.
91. Posada IS, Barriales V; LASAF Pilot Study Group. Alternate-day dosing of aspirin in atrial fibrillation. Am Heart J. 1999;138(1, pt 1):137-143.
92. Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis. 1999;9(4):215-217.
93. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349(11):1019-1026.
94. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335(8):540-546.
95. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120(11):897-902.
96. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-1833.
97. Biblo LA, Yuan Z, Quan KJ, Mackall JA, Rimm AA. Risk of stroke in patients with atrial flutter. Am J Cardiol. 2001;87(3):346-349, A9.
98. Halligan SC, Gersh BJ, Brown RD Jr, et al. The natural history of lone atrial flutter. Ann Intern Med. 2004;140(4):265-268.
99. Neumann T, Erdogan A, Dill T, et al. Asymptomatic recurrences of atrial fibrillation after pulmonary vein isolation. Europace. 2006;8(7):495-498.
100. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation. 1994;89(1):224-227.
101. Oral H, Chugh A, Ozaydin M, et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation. 2006;114(8):759-765. Epub 2006 Aug 14.
102. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903- 1912.
103. Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004;35(10):2362-2367. Epub 2004 Aug 26.
104. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis [published correction appears in JAMA. 2000;284(1):45]. JAMA. 1999;282(21):2058-2067.
105. Ruiz-Nodar JM, Marín F, Hurtado JA, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol. 2008;51(8):818-825.
106. Francescone S, Halperin JL. "Triple therapy" or triple threat? Balancing the risks of antithrombotic therapy for patients with atrial fibrillation and coronary stents [editorial]. J Am Coll Cardiol. 2008;51(8):826-827.
107. Khan IA. Atrial stunning: determinants and cellular mechanisms. Am Heart J. 2003;145(5):787-794.
108. Falcone RA, Morady F, Armstrong WF. Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation. Am J Cardiol. 1996;78(4):435-439.
109. Antonielli E, Pizzuti A, Bassignana A, et al. Transesophageal echocardiographic evidence of more pronounced left atrial stunning after chemical (propafenone) rather than electrical attempts at cardioversion from atrial fibrillation. Am J Cardiol. 1999;84(9):1092-1096, A9-A10.
110. Manning WJ, Silverman DI, Katz SE, et al. Temporal dependence of the return of atrial mechanical function on the mode of cardioversion of atrial fibrillation to sinus rhythm. Am J Cardiol. 1995;75(8):624-626.
111. Grimm RA, Leung DY, Black IW, Stewart WJ, Thomas JD, Klein AL. Left atrial appendage "stunning" after spontaneous conversion of atrial fibrillation demonstrated by transesophageal Doppler echocardiography. Am Heart J. 1995;130(1):174-176.
112. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG; Stroke Prevention in Atrial Fibrillation III Investigators. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol. 1998;31(7):1622-1626.
113. Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for "atrial stunning" as a mechanism of thromboembolic complications. J Am Coll Cardiol. 1994;23(2):307-316.
114. Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol. 1998;82(12):1545-1547, A8.
115. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol. 1969;23(2):208-216.
116. Kinch JW, Davidoff R. Prevention of embolic events after cardioversion of atrial fibrillation: current and evolving strategies. Arch Intern Med. 1995;155(13):1353-1360.
117. Collins LJ, Silverman DI, Douglas PS, Manning WJ. Cardioversion of nonrheumatic atrial fibrillation: reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. Circulation. 1995;92(2):160-163.
118. Stellbrink C, Nixdorff U, Hofmann T, et al; ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation. 2004;109(8):997-1003. Epub 2004 Feb 16.
119. Klein AL, Jasper SE, Katz WE, et al; ACUTE II Steering and Publications Committe for the ACUTE II Investigator. The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomized multicentre study. Eur Heart J. 2006;27(23):2858-2865. Epub 2006 Nov 10.
120. Klein AL, Grimm RA, Murray RD, et al; Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344(19):1411-1420.
121. Mehta D, Baruch L. Thromboembolism following cardioversion of "common" atrial flutter: risk factors and limitations of transesophageal echocardiography. Chest. 1996;110(4):1001-1003.
122. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41(10):1690-1696.
123. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356(9244):1789-1794.
124. Opolski G, Torbicki A, Kosior DA, et al; Investigators of the Polish HOT CAFE Trial. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest. 2004;126(2):476-486.
125. Van Gelder IC, Hagens VE, Bosker HA, et al; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840.
126. Stabile G, Bertaglia E, Senatore G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J. 2006;27(2):216-221. Epub 2005 Oct 7.
127. Jaïs P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 Study. Circulation. 2008;118(24):2498-2505. Epub 2008 Nov 24.
128. Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol. 2006;48(11):2340-2347. Epub 2006 Oct 16.
129. Lafuente-Lafuente C, Mouly S, Longás-Tejero MA, Mahé I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006;166(7):719-728.
130. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2007;(4):CD005049.
131. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321(6):406-412.
132. Dale KM, White CM. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007;41(4):599-605. Epub 2007 Mar 27.
133. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24(16):1481-1487.
134. Hohnloser SH, Dorian P, Straub M, Beckmann K, Kowey P. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J Am Coll Cardiol. 2004;44(1):99-104.
135. Freestone B, Lip GY. Tedisamil: a new novel antiarrhythmic. Expert Opin Investig Drugs. 2004;13(2):151-160.
136. Blaauw Y, Crijns HJ. Atrial fibrillation: insights from clinical trials and novel treatment options. J Intern Med. 2007;262(6):593-614.
137. Lévy S. Do we need pharmacological therapy for atrial fibrillation in the ablation era? J Interv Card Electrophysiol. 2006;17(3):189-194.
138. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther. 2008;15(1):36-43.
139. Sakabe M, Shiroshita-Takeshita A, Maguy A, et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation. 2007;116(19):2101-2109. Epub 2007 Oct 22.
140. Howard PA, Barnes BJ. Potential use of statins to prevent atrial fibrillation after coronary artery bypass surgery. Ann Pharmacother. 2008;42(2):253-258. Epub 2008 Jan 15.
141. Asirvatham SJ. Pulmonary vein-related manuevers: part I. Heart Rhythm. 2007;4(4):538-544. Epub 2007 Jan 12.
142. Asirvatham SJ. Pacing manuevers for nonpulmonary vein sources: part II. Heart Rhythm. 2007;4(5):681-685. Epub 2007 Jan 12.
143. Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005;111(9):1100-1105. Epub 2005 Feb 21.
144. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med. 1995;155(5):469-473.
145. Jalife J, Berenfeld O, Mansour M. Mother rotors and fibrillatory conduction: a mechanism of atrial fibrillation. Cardiovasc Res. 2002;54(2):204-216.
146. Moe GK, Rheinboldt WC, Abildskov JA. A computer model of atrial fibrillation. Am Heart J. 1964;67:200-220.
147. Chen SA, Hsieh MH, Tai CT, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation. 1999;100(18):1879-1886.
148. Haïssaguerre M, Hocini M, Sanders P, et al. Localized sources maintaining atrial fibrillation organized by prior ablation. Circulation. 2006;113(5):616-625.
149. Jaïs P, Haïssaguerre M, Shah DC, et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation. 1997;95(3):572-576.
150. Nathan H, Eliakim M. The junction between the left atrium and the pulmonary veins: an anatomic study of human hearts. Circulation. 1966;34(3):412-422.
151. Asirvatham SJ. Anatomy of the coronary sinus. In: Yu CM, Hayes DL, Auricchio A, eds. Cardiac Resynchronization Therapy. Malden, MA: Blackwell/Futura; 2006:211-238.
152. Asirvatham SJ. Supraventricular tachycardia: diagnosis and treatment. In: Murphy JG, Lloyd MA, eds. Mayo Clinic Cardiology: Concise Textbook. 3rd ed. Rochester, MN: Mayo Clinic Scientific Press; 2007:379-387.
153. Nademanee K, McKenzie J, Kosar E, et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol. 2004;43(11):2044-2053.
154. Oral H, Chugh A, Good E, et al. A tailored approach to catheter ablation of paroxysmal atrial fibrillation. Circulation. 2006;113(15):1824-1831. Epub 2006 Apr 10.
155. Nakagawa H, Scherlag BJ, Lockwood D, et al. Localization of left atrial autonomic ganglionated plexuses using endocardial and epicardial high frequency stimulation in patients with atrial fibrillation [abstract AB6-1]. Heart Rhythm. 2005;2(5)(suppl 1):S10-S11.
156. Schauerte P, Scherlag BJ, Pitha J, et al. Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. Circulation. 2000;102(22):2774-2780.
157. Hsieh MH, Chiou CW, Wen ZC, et al. Alterations of heart rate variability after radiofrequency catheter ablation of focal atrial fibrillation originating from pulmonary veins. Circulation. 1999;100(22):2237-2243.
158. Karch MR, Zrenner B, Deisenhofer I, et al. Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies. Circulation. 2005;111(22):2875-2880. Epub 2005 May 31.
159. Nilsson B, Chen X, Pehrson S, Køber L, Hilden J, Svendsen JH. Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: a randomized trial of the ostial versus the extraostial ablation strategy. Am Heart J. 2006;152(3):537.e1-537.e8.
160. Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS Expert Consensus Statement on catheter and surgical ablation of atrial fibrilla- tion: recommendations for personnel, policy, procedures and follow-up: a report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation [published correction appears in Heart Rhythm. 2009;6(1):148]. Heart Rhythm. 2007;4(6):816-861. Epub 2007 Apr 30.
161. Oral H, Veerareddy S, Good E, et al. Prevalence of asymptomatic recurrences of atrial fibrillation after successful radiofrequency catheter ablation. J Cardiovasc Electrophysiol. 2004;15(8):920-924.
162. Haïssaguerre M, Jaïs P, Shah DC, et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation. 2000;101(12):1409-1417.
163. Marrouche NF, Dresing T, Cole C, et al. Circular mapping and ablation of the pulmonary vein for treatment of atrial fibrillation: impact of different catheter technologies. J Am Coll Cardiol. 2002;40(3):464-474.
164. Oral H, Knight BP, Tada H, et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation. 2002;105(9):1077-1081.
165. Packer DL, Asirvatham S, Munger TM. Progress in nonpharmacologic therapy of atrial fibrillation. J Cardiovasc Electrophysiol. 2003;14(12) (suppl):S296-S309.
166. Pappone C, Oreto G, Rosanio S, et al. Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation. 2001;104(21):2539-2544.
167. Earley MJ, Abrams DJ, Staniforth AD, Sporton SC, Schilling RJ. Catheter ablation of permanent atrial fibrillation: medium term results. Heart. 2006;92(2):233-238. Epub 2005 Aug 23.
168. Haïssaguerre M, Hocini M, Sanders P, et al. Catheter ablation of longlasting persistent atrial fibrillation: clinical outcome and mechanisms of subsequent arrhythmias. J Cardiovasc Electrophysiol. 2005;16(11):1138- 1147.
169. Haïssaguerre M, Jaïs P, Shah D, et al. Catheter ablation of chronic atrial fibrillation targeting the reinitiating triggers. J Cardiovasc Electrophysiol. 2000;11(1):2-10.
170. Berkowitsch A, Greiss H, Vukajlovic D, et al. Usefulness of atrial fibrillation burden as a predictor for success of pulmonary vein isolation. Pacing Clin Electrophysiol. 2005;28(12):1292-1301.
171. Pappone C, Santinelli V, Manguso F, et al. A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome. N Engl J Med. 2003;349(19):1803-1811.
172. Weerasooriya R, Jaïs P, Hocini M, et al. Effect of catheter ablation on quality of life of patients with paroxysmal atrial fibrillation. Heart Rhythm. 2005;2(6):619-623.
173. Hocini M, Jaïs P, Haïssaguerre M, Garrigue S, le Metayer P, Clementy J. Radiofrequency ablation of atrial fibrillation [in French]. Ann Cardiol Angeiol (Paris). 2003;52(4):258-263.
174. Packer DL, Keelan P, Munger TM, et al. Clinical presentation, investigation, and management of pulmonary vein stenosis complicating ablation for atrial fibrillation. Circulation. 2005;111(5):546-554.
175. Tada H, Naito S, Kurosaki K, et al. Segmental pulmonary vein isolation for paroxysmal atrial fibrillation improves quality of life and clinical outcomes. Circ J. 2003;67(10):861-865.
176. Ahmed J, Sohal S, Malchano ZJ, Holmvang G, Ruskin JN, Reddy VY. Three-dimensional analysis of pulmonary venous ostial and antral anatomy: implications for balloon catheter-based pulmonary vein isolation. J Cardiovasc Electrophysiol. 2006;17(3):251-255.
177. Arentz T, Jander N, von Rosenthal J, et al. Incidence of pulmonary vein stenosis 2 years after radiofrequency catheter ablation of refractory atrial fibrillation. Eur Heart J. 2003;24(10):963-969.
178. Robbins IM, Colvin EV, Doyle TP, et al. Pulmonary vein stenosis after catheter ablation of atrial fibrillation. Circulation. 1998;98(17):1769-1775.
179. Saad EB, Rossillo A, Saad CP, et al. Pulmonary vein stenosis after radiofrequency ablation of atrial fibrillation: functional characterization, evolution, and influence of the ablation strategy. Circulation. 2003;108(25):3102-3107. Epub 2003 Nov 17.
180. Bruce CJ, Friedman PA, Narayan O, et al. Early heparinization decreases the incidence of left atrial thrombi detected by intracardiac echocardiography during radiofrequency ablation for atrial fibrillation. J Interv Card Electrophysiol. 2008;22(3):211-219. Epub 2008 Jun 21.
181. Cummings JE, Schweikert RA, Saliba WI, et al. Brief communication: atrial-esophageal fistulas after radiofrequency ablation. Ann Intern Med. 2006;144(8):572-574.
182. Pappone C, Oral H, Santinelli V, et al. Atrio-esophageal fistula as a complication of percutaneous transcatheter ablation of atrial fibrillation. Circulation. 2004;109(22):2724-2726. Epub 2004 May 24.
183. Schley P, Gülker H, Horlitz M. Atrio-oesophageal fistula following circumferential pulmonary vein ablation: verification of diagnosis with multislice computed tomography. Europace. 2006;8(3):189-190. Epub 2006 Feb 7.
184. Sosa E, Scanavacca M. Left atrial-esophageal fistula complicating radiofrequency catheter ablation of atrial fibrillation [editorial]. J Cardiovasc Electrophysiol. 2005;16(3):249-250.
185. Bunch TJ, Nelson J, Foley T, et al. Temporary esophageal stenting allows healing of esophageal perforations following atrial fibrillation ablation procedures. J Cardiovasc Electrophysiol. 2006;17(4):435-439.